drugset / Trial / NCT04677452
Dose Exploration Study OF JWCAR129, BCMA-Targeted CART for RRMM
NaSingle-groupOpen-labelTreatment
Summary
This is an open-label, Phase 1 dose exploration study to evaluate the safety and tolerability and to determine recommended Phase 2 dose(s) of JWCAR129, a CAR T-cell product that targets B-cell maturation antigen (BCMA), in adult subjects with relapsed and/or refractory multiple myeloma.
Timeline
- Start
- 2020-12
- Primary completion
- 2022-03
- Completion
- 2024-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | JWCAR129 | Cell therapy | — | Intravenous |
Indications
No indication recorded.